Release Date: June 4, 2022
Expiration Date: August 30, 2022
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 3, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational program is directed toward medical oncologists interested in the treatment and management of melanoma. Other healthcare professionals interested in the treatment and management of patients with melanoma will be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Assess recent clinical trial evidence concerning the safety and efficacy of immunotherapy used as single-agents or combination strategies for melanoma management
- Evaluate the efficacy and safety of targeted therapies, including BRAF/MEK inhibition, in the management of melanoma
- Describe treatment-related adverse events and appropriate management strategies for patients with melanoma
- Utilize approaches to optimize clinical decision-making across multiple lines of care in melanoma
Jason J. Luke, MD, FACP
Director of the Cancer Immunotherapeutics Center
Associate Professor of Medicine
University of Pittsburgh Medical Center Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosures: Grant/Research Support: To institution for clinical trials: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, F-Star, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, MacroGenics, Merck, Moderna, Nektar, Next Cure, Numab, Palleon, Pfizer, Replimune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor; Consultant: AbbVie, Bayer, Bristol-Myers Squibb, Castle, Checkmate, Codiak, Crown, Day One, Duke St, EMD Serono, Endeavor, Flame, Genentech, Gilead, Glenmark, HotSpot, Kadmon, Janssen, Ikena, Immunocore, Incyte, IO Biotech, MacroGenics, Merck, Nektar, Novartis, Partner, Pfizer, Regeneron, Roivant, Servier, Stingthera, Synlogic, Synthekine; Other: Data and safety monitoring board: AbbVie, Immutep, Evaxion. Advisory boards: 7 Hills, Bright Peak, Exo, F-Star, Inzen, RefleXion, Xilio (stock), Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavupharma, NeoTX, Onc.AI, OncoNano, Pyxis, STipe, Tempest.
Evan J. Lipson, MD
Associate Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosures: Grant/Research Support: Bristol Myers Squibb, Merck, Sanofi Regeneron; Consultant: Bristol Myers Squibb, Novartis, EMD Serono, Array BioPharma, MacroGenics, Merck, Sanofi Regeneron, Genentech, Odonate Therapeutics, OncoSec, Eisai, Natera, Instil Bio, Nektar, Pfizer, Rain Therapeutics.
Yana G. Najjar, MD
Assistant Professor of Medicine
Director, Clinical and Translational Research Center
University of Pittsburgh Medical Center Hillman Cancer Center
University of Pittsburgh School of Medicine
Pittsburgh, PA
Disclosures: Grant/Research Support: Merck, Pfizer, Bristol Myers Squibb; Speakers’ Bureau: Pfizer.
Daniel Olson, MD
Assistant Professor of Medicine (Hematology/Oncology)
University of Chicago Medicine
Chicago, IL
Daniel Olson, MD has no relevant financial relationships with ineligible companies.
Sapna Patel, BA, MD
Associate Professor
Director, Uveal Melanoma Program
Director, Melanoma Fellowship Program
Director, Online Media
Department of Melanoma Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Bristol Myers Squibb, Foghorn Therapeutics, IDEAYA, InxMed, LvGen, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Biosystems, TriSalus Life Sciences; Consultant: Delcath, Advance Knowledge in Healthcare, Cardinal Health, Immunocore, Novartis, TriSalus Life Sciences; Shareholder: Pfizer, Amgen, Merck.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
